[go: up one dir, main page]

WO2004085642A1 - Gene lie a l'arthrite et son utilisation dans l'examen de l'arthrite - Google Patents

Gene lie a l'arthrite et son utilisation dans l'examen de l'arthrite Download PDF

Info

Publication number
WO2004085642A1
WO2004085642A1 PCT/JP2004/004352 JP2004004352W WO2004085642A1 WO 2004085642 A1 WO2004085642 A1 WO 2004085642A1 JP 2004004352 W JP2004004352 W JP 2004004352W WO 2004085642 A1 WO2004085642 A1 WO 2004085642A1
Authority
WO
WIPO (PCT)
Prior art keywords
arthritis
midkine
remedy
onset
examining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/004352
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Muramatsu
Kiyoko Maruyama
Hisako Muramatsu
Naoki Ishiguro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2005504126A priority Critical patent/JP4646070B2/ja
Publication of WO2004085642A1 publication Critical patent/WO2004085642A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

L'invention vise à déterminer un facteur lié à l'apparition d'arthrite, notamment de la polyarthrite rhumatoïde. L'invention vise ensuite à fournir un procédé de sélection d'un médicament pour l'arthrite ciblant le facteur ainsi trouvé, un médicament et un réactif d'examen pour l'arthrite. Comparé à la souris de type sauvage, l'incidence de l'arthrite chez la souris midkine-knockout est relativement faible. La plupart des patients souffrant d'arthrite ont des niveaux élevés de midkine dans le sérum et la synovie, ce qui laisse présumer que l'expression de midkine est étroitement lié à la polyarthrite rhumatoïde. La fréquence de l'apparition de l'arthrite induite par les anticorps est élevée par l'administration de midkine à la souris à déficience en gène de la midkine.
PCT/JP2004/004352 2003-03-27 2004-03-26 Gene lie a l'arthrite et son utilisation dans l'examen de l'arthrite Ceased WO2004085642A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005504126A JP4646070B2 (ja) 2003-03-27 2004-03-26 関節炎関連遺伝子及びこれの関節炎検査等への利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-127573 2003-03-27
JP2003127573 2003-03-27

Publications (1)

Publication Number Publication Date
WO2004085642A1 true WO2004085642A1 (fr) 2004-10-07

Family

ID=33095351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/004352 Ceased WO2004085642A1 (fr) 2003-03-27 2004-03-26 Gene lie a l'arthrite et son utilisation dans l'examen de l'arthrite

Country Status (2)

Country Link
JP (1) JP4646070B2 (fr)
WO (1) WO2004085642A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055378A1 (fr) * 2005-11-14 2007-05-18 Cell Signals Inc. Procede de traitement ou de prevention d’une maladie associee a un trouble fonctionnel des lymphocytes t regulateurs
WO2008059877A1 (fr) 2006-11-14 2008-05-22 Ribomic Inc. Aptamère contre la midkine et son utilisation
WO2008059616A1 (fr) 2006-11-14 2008-05-22 Medical Therapies Limited Anticorps reconnaissant le domaine c de la midkine
WO2014021339A1 (fr) 2012-07-30 2014-02-06 国立大学法人名古屋大学 Anticorps monoclonal dirigé contre la protéine midkine d'origine humaine
WO2020022499A1 (fr) * 2018-07-27 2020-01-30 国立大学法人大阪大学 Composition pour l'inhibition du vieillissement, la prévention, l'atténuation ou le traitement de maladies liées à l'âge, ou le prolongement de la durée de vie

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591880A (ja) * 1991-02-28 1993-04-16 Nippon Koutai Kenkyusho:Kk ヒトｍｋ遺伝子
EP0569703A2 (fr) * 1992-04-24 1993-11-18 American Cyanamid Company Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK
WO1994013800A2 (fr) * 1992-12-11 1994-06-23 Cancer Research Campaign Technology Limited Preparation a base de proteine mk et son utilisation dans les cultures cellulaires
WO1999003493A1 (fr) * 1997-07-14 1999-01-28 Meiji Milk Products Co., Ltd. Medicaments contenant midkine en tant principe actif ou inhibiteurs desdits medicaments
WO1999038971A1 (fr) * 1998-02-02 1999-08-05 Meiji Milk Products Co., Ltd. Proteine se liant a la midkine
JP2000072799A (ja) * 1998-08-24 2000-03-07 Meiji Milk Prod Co Ltd チロシンに富むレセプター様タンパク質
JP2004012447A (ja) * 2002-06-05 2004-01-15 Takashi Muramatsu リウマチの診断法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591880A (ja) * 1991-02-28 1993-04-16 Nippon Koutai Kenkyusho:Kk ヒトｍｋ遺伝子
EP0569703A2 (fr) * 1992-04-24 1993-11-18 American Cyanamid Company Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK
WO1994013800A2 (fr) * 1992-12-11 1994-06-23 Cancer Research Campaign Technology Limited Preparation a base de proteine mk et son utilisation dans les cultures cellulaires
WO1999003493A1 (fr) * 1997-07-14 1999-01-28 Meiji Milk Products Co., Ltd. Medicaments contenant midkine en tant principe actif ou inhibiteurs desdits medicaments
WO1999038971A1 (fr) * 1998-02-02 1999-08-05 Meiji Milk Products Co., Ltd. Proteine se liant a la midkine
JP2000072799A (ja) * 1998-08-24 2000-03-07 Meiji Milk Prod Co Ltd チロシンに富むレセプター様タンパク質
JP2004012447A (ja) * 2002-06-05 2004-01-15 Takashi Muramatsu リウマチの診断法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MURAMATSU T.: "MIDKINE AND PLEIOTROPHIN: TWO RELATED PROTEINS INVOLVED IN DEVELOPMENT, SURVIVAL, INFLAMMATION AND TUMORIGENESIS", JOURNAL OF BIOCHEMISTRY, vol. 132, no. 3, September 2002 (2002-09-01), pages 359 - 371, XP009009323 *
TAKADA T. ET AL: "MIDKINE A RETINOIC ACID-INDUCIBLE HEPARIN-BINDING CYTOKINE IN INFLAMMATORY RESPONSES: CHEMOTACTIC ACTIVITY TO NEUTROPHILS AND ASSOCIATION WITH INFLAMMATORY SYNOVITIS", JOURNAL OF BIOCHEMISTRY, vol. 122, no. 2, August 1997 (1997-08-01), pages 453 - 458, XP002911186 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055378A1 (fr) * 2005-11-14 2007-05-18 Cell Signals Inc. Procede de traitement ou de prevention d’une maladie associee a un trouble fonctionnel des lymphocytes t regulateurs
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
JP5398987B2 (ja) * 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
US8716230B2 (en) 2005-11-14 2014-05-06 Ribomic Inc. Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells
WO2008059877A1 (fr) 2006-11-14 2008-05-22 Ribomic Inc. Aptamère contre la midkine et son utilisation
WO2008059616A1 (fr) 2006-11-14 2008-05-22 Medical Therapies Limited Anticorps reconnaissant le domaine c de la midkine
US8080649B2 (en) 2006-11-14 2011-12-20 Ribomic Inc. Aptamer against midkine and use thereof
JP5190573B2 (ja) * 2006-11-14 2013-04-24 株式会社リボミック ミッドカインに対するアプタマー及びその使用
EP2803674A2 (fr) 2006-11-14 2014-11-19 Medical Therapies Limited Anticorps reconnaissant le domaine C de la midkine
WO2014021339A1 (fr) 2012-07-30 2014-02-06 国立大学法人名古屋大学 Anticorps monoclonal dirigé contre la protéine midkine d'origine humaine
US9840552B2 (en) 2012-07-30 2017-12-12 National University Corporation Nagoya University Monoclonal antibody against human midkine
WO2020022499A1 (fr) * 2018-07-27 2020-01-30 国立大学法人大阪大学 Composition pour l'inhibition du vieillissement, la prévention, l'atténuation ou le traitement de maladies liées à l'âge, ou le prolongement de la durée de vie

Also Published As

Publication number Publication date
JPWO2004085642A1 (ja) 2006-06-29
JP4646070B2 (ja) 2011-03-09

Similar Documents

Publication Publication Date Title
Petri et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
Yap et al. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development
Nerviani et al. A pauci-immune synovial pathotype predicts inadequate response to TNFα-blockade in rheumatoid arthritis patients
Carvalheiro et al. CD8+ T cell profiles in patients with rheumatoid arthritis and their relationship to disease activity
Maksymowych Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy
Lee Classification systems for chronic graft-versus-host disease
Szodoray et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system
Risselada et al. The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review
Klaasen et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study
Petrackova et al. Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay
Jin et al. CD4+ CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren’s syndrome
Xu et al. Population pharmacokinetics of golimumab, an anti‐tumor necrosis factor‐α human monoclonal antibody, in patients with psoriatic arthritis
Chong et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients
EP2293209A3 (fr) Procédé et appareil pour détecter et prédire les anomalies biologiques et troubles cérébraux
EP3230745B1 (fr) Biomarqueurs d'auto-anticorps dans le plasma pour cancer du sein de type basal
Diaconu et al. Practical significance of biomarkers in axial spondyloarthritis: updates on diagnosis, disease activity, and prognosis
WO2012158954A1 (fr) Méthodes de diagnostic et de traitement de maladies ou affections pulmonaires
AU2007247742B2 (en) Dissolved protein arthritis markers
WO2004068114A3 (fr) Ameliorations apportees a un procede et a un systeme de detection et/ou de prediction d'anomalies biologiques, telles que des troubles cerebraux
Hu et al. Expression of RANKL by peripheral neutrophils and its association with bone mineral density in COPD
Egler et al. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma
Lindblom et al. Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights
Takeuchi Biomarkers as a treatment guide in rheumatoid arthritis
Zhou et al. Short‐term effect of low‐dose rituximab on myasthenia gravis with muscle‐specific tyrosine kinase antibody
WO2004085642A1 (fr) Gene lie a l'arthrite et son utilisation dans l'examen de l'arthrite

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005504126

Country of ref document: JP

122 Ep: pct application non-entry in european phase